<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        40-119-82
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1982
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BALKATRIN TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SULFAMETHOXAZOLE,TRIMETHOPRIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400,80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        8.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APM" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APM
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01EE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Balkatrin 80 mg/400 mg Tablets (called &lsquo;Balkatrin&rsquo; in this leaflet) is a combination of two different antibiotics called sulfamethoxazole and trimethoprim (also known as co-trimoxazole), which is used to treat infections caused by certain bacteria. Like all antibiotics, trimethoprim and sulfamethoxazole only works against some types of bacteria. This means that it is only suitable for treating some types of infections.</p><p><br /><strong>Balkatrin can be used to treat or prevent:</strong></p><ul><li>Lung infections (pneumonia or PJP) caused by a bacteria called Pneumocystis jirovecii.</li><li>Infections caused by a bacteria called Toxoplasma (toxoplasmosis).</li></ul><p>&nbsp;</p><p><strong>Balkatrin can be used to treat:</strong></p><ul><li>Urinary bladder or urinary tract infections (water infections).</li><li>Respiratory tract infections such as bronchitis.</li><li>Ear infections such as otitis media.</li><li>An infection called nocardiosis; which can affect the lungs, skin and brain.</li></ul><p>&nbsp;</p><p>Balkatrin tablets are indicated in children (&gt;12 to &lt;18 years old) and adults (&gt;18 years old).</p><p><br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Balkatrin if:</strong></p><ul><li>You are allergic to sulfamethoxazole, trimethoprim or co-trimoxazole or any of the other ingredients of this medicine (listed in section 6).</li><li>You are allergic to sulphonamide medicines. Examples include sulphonylureas (such as gliclazide and glibenclamide) or thiazide diuretics (such as bendroflumethiazide &ndash; a water tablet).</li><li>You have severe liver or severe kidney problems.</li><li>You have ever had a problem with your blood causing bruises or bleeding (thrombocytopenia).</li><li>You have been told that you have a rare blood problem called porphyria, which can affect your skin or nervous system.</li><li>Trimethoprim and sulfamethoxazole should not be given to infants during the first 6 weeks of life.</li></ul><p>&nbsp;</p><p>If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Balkatrin.</p><p><br /><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Balkatrin:</p><ul><li>If you have severe allergies or asthma.</li><li>Potentially life-threatening skin rashes (Stevens- Johnson syndrome, toxic epidermal necrolysis drug reaction with eosinophilia and systemic symptoms) have been reported with the use of trimethoprim and sulfamethoxazole appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk.</li><li>At the start of treatment, the occurrence of a generalised skin redness with pustules, accompanied by fever, should raise the suspicion of a serious reaction called generalised acute exanthematous pustulosis (AGEP) (see section 4).</li><li>Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes).</li><li>These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin.</li><li>The highest risk for occurrence of serious skin reactions is within the first weeks of treatment.</li><li>If you have developed Stevens-Johnson syndrome, toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms with the use of Balkatrin you must not be re-started on Balkatrin at any time.</li><li>If you develop a rash or these skin symptoms, stop taking Balkatrin, seek urgent advice from a doctor and tell him that you are taking this medicine.</li><li>Haemophagocytic lymphohistiocytosis</li></ul><p style="margin-left:40px">There have been very rare reports about excessive immune reactions due to a dysregulated activation of white blood cells resulting in inflammations (haemophagocytic lymphohistiocytosis), which can be life-threatening if not diagnosed and treated early. If you experience multiple symptoms such as fever, swollen glands, feeling weak, lightheaded, shortness of breath, bruising, or skin rash simultaneously or with a slight delay, contact your doctor immediately.</p><ul><li>If you develop an unexpected worsening of cough and shortness of breath, inform your doctor immediately.</li><li>If you have been told that you are at risk for a rare blood disorder called porphyria.</li><li>If you don&rsquo;t have enough folic acid (a vitamin) in your body - which can make your skin pale and make you feel tired, weak and breathless. This is known as anaemia.</li><li>If you have a disease called glucose-6-phosphate dehydrogenase deficiency, which can cause jaundice or spontaneous destruction of red blood cells.</li><li>If you have a problem with your metabolism called phenylketonuria and are not on a special diet to help your condition.</li><li>If you are elderly.</li><li>If you have a kidney disease.</li><li>If you have a severe blood disorder, such as a low number of red blood cells (anaemia), a low number of white blood cells (leucopenia) or a low number of platelets, which may cause bleeding and bruising (thrombocytopenia)</li><li>If you are underweight or malnourished.</li><li>If you have been told by your doctor that you have a lot of potassium in your blood. Concomitant administration of trimethoprim and sulfamethoxazole with certain medicines, potassium supplements and food rich in potassium may lead to severe hyperkalaemia (increased potassium blood level). The symptoms of severe hyperkalaemia might include muscle cramps, irregular heart rhythm, diarrhoea, nausea, dizziness or headache.</li></ul><p>&nbsp;</p><p><strong>Other medicines and Balkatrin</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or may take any other medicines. This is because Balkatrin can affect the way some medicines work. Also some other medicines can affect the way Balkatrin works.</p><p><br />In particular tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>Diuretics (water tablets), which help increase the amount of urine you produce.</li><li>Pyrimethamine, used to treat and prevent malaria, and to treat diarrhoea.</li><li>Ciclosporin, used after organ transplant surgeries.</li><li>Blood thinners such as warfarin.</li><li>Phenytoin, used to treat epilepsy (fits).</li><li>Medicines used to treat diabetes, such as glibenclamide, glipizide or tolbutamide (sulphonylureas) and repaglinide.</li><li>Rifampicin, an antibiotic.</li><li>Medicines to treat problems with the way your heart beats such as digoxin or procainamide.</li><li>Amantadine, used to treat Parkinson&rsquo;s disease, multiple sclerosis, &lsquo;flu&rsquo; or shingles.</li><li>Medicines to treat HIV (Human Immunodeficiency Virus), called zidovudine or lamivudine.</li><li>Medicines that can increase the amount of potassium in your blood, such as diuretics (water tablets, which help increase the amount of urine you produce, such as spironolactone), steroids (like prednisolone), digoxin or ACE inhibitors (may be used to treat high blood pressure or some heart problems).</li><li>Azathioprine, may be used in patients following organ transplant or to treat immune system disorders or inflammatory bowel disease.</li><li>Methotrexate, a medicine used to treat certain cancers or certain diseases affecting your immune system.</li><li>Folinic acid.</li><li>Contraceptive medicines.</li></ul><p>&nbsp;</p><p><strong>Balkatrin with food and drink</strong><br />You should take Balkatrin with some food or drink. This will stop you feeling sick (nausea) or having diarrhoea. Although it is better to take it with food, you can still take it on an empty stomach.</p><p><br />Drink plenty of fluid such as water while you are taking Balkatrin.</p><p><br /><strong>Pregnancy and breast feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><br /><strong>Driving and using machines</strong><br />Effects on the ability to drive and operate machinery in patients taking this medicine have not been studied.</p><p><br /><strong>Balkatrin contains benzoic acid and sodium</strong><br />Balkatrin contains benzoic acid. Each tablet of Balkatrin 80 mg/400 mg Tablets contains 0.30 mg benzoic acid.</p><p><br />Balkatrin contains sodium. Each tablet of Balkatrin 80 mg/400 mg Tablets contains 0.2 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><br /><strong>Standard Dose</strong><br /><em>Standard dosage recommendations for acute infections</em></p><ul><li>Adults (&gt;18 years old)</li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td colspan="2"><p><strong>Standard Dosage</strong></p></td></tr><tr><td style="width:230px"><strong>Age</strong></td><td style="width:268px"><strong>Tablets</strong></td></tr><tr><td style="width:230px">&gt;18 years old</td><td style="width:268px">tablets every 12 hours <sup>2</sup></td></tr></tbody></table><p>&nbsp;</p><ul><li>Children over 12 years old (&gt;12 to &lt;18 years old)</li></ul><p>The standard dosage for children is equivalent to approximately 6 mg trimethoprim and 30 mg sulfamethoxazole per kg body weight per day, given in two equally divided doses. The schedules for children are according to the child&rsquo;s age and weight and provided in the table below:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>Age</strong></td><td><strong>Tablets</strong></td></tr><tr><td>&gt;12 to &lt;18 years old</td><td>2 tablets every 12 hours</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>Body weight</strong></td><td><strong>Tablets</strong></td></tr><tr><td>&gt;27 kg</td><td>1 tablet every 12 hours</td></tr><tr><td>&gt;53 kg</td><td>2 tablets every 12 hours</td></tr></tbody></table><ul><li>Balkatrin should be taken for at least five days.</li><li>Make sure that you finish the course of Balkatrin which your doctor has prescribed.</li></ul><p>&nbsp;</p><p>Balkatrin 80 mg/400 mg Tablets are not usually given to children under 12 years old. If they have been given to your child under 12 years please speak to your doctor or pharmacist for more information.</p><p><br /><strong>Special Dose</strong><br />The dose of Balkatrin and how long you need to take it depends on the infection you have and how bad it is. Your doctor may prescribe you a different dose or length of course of Balkatrin to:</p><ul><li>Treat urinary tract (water) infections.</li><li>Treat and prevent lung infections caused by the bacteria Pneumocystis jirovecii.</li><li>Treat infections caused by the bacteria Toxoplasma (toxoplasmosis) or Nocardia (nocardiosis).</li></ul><p>&nbsp;</p><p>If you have kidney problems your doctor may:</p><ul><li>Prescribe a lower dose of Balkatrin.</li><li>Take blood to test whether the medicine is working properly.</li></ul><p>&nbsp;</p><p>If you take Balkatrin for a long time your doctor may:</p><ul><li>Take blood to test whether the medicine is working properly.</li><li>Prescribe folic acid (a vitamin) for you to take at the same time as Balkatrin.</li></ul><p><br /><strong>If you take more Balkatrin than you should</strong><br />If you take more Balkatrin than you should, talk to your doctor or go to a hospital straight away. Take the medicine pack with you.</p><p><br />If you have taken too much Balkatrin you may:</p><ul><li>Feel or be sick.</li><li>Feel dizzy or confused.</li></ul><p>&nbsp;</p><p><strong>If you forget to take Balkatrin</strong></p><ul><li>If you forget to take a dose, take it as soon as you remember it.</li><li>Do not take a double dose to make up for the forgotten dose.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines this medicine can cause side effects, although not everybody gets them. You may experience the following side effects with this medicine.</p><p><br />Stop taking trimethoprim and sulfamethoxazole and tell your doctor immediately if you have an allergic reaction.</p><p><br /><em><strong>Chances of an allergic reaction is very rare (fewer than 1 in 10,000 people are affected), signs of an allergic reaction include:</strong></em><br /><strong>Allergic reactions</strong></p><ul><li>Difficulty in breathing.</li><li>Fainting.</li><li>Swelling of face.</li><li>Swelling of mouth, tongue or throat which may be red and painful and/or cause difficulty in swallowing.</li><li>Chest pain.</li><li>Red patches on the skin.</li></ul><p>&nbsp;</p><p><strong>Very Common (more than 1 in 10 people)</strong></p><ul><li>High levels of potassium in your blood, which can cause abnormal heart beats (palpitations).</li></ul><p><br /><strong>Common (less than 1 in 10 people)</strong></p><ul><li>A fungal infection called thrush or candidiasis which can affect your mouth or vagina.</li><li>Headache.</li><li>Feeling sick (nausea).</li><li>Diarrhoea.</li><li>Skin rashes.</li></ul><p>&nbsp;</p><p><strong>Uncommon (less than 1 in 100)</strong></p><ul><li>Being sick (vomiting).</li></ul><p><br /><strong>Very Rare (less than 1 in 10,000 people)</strong></p><ul><li>Fever (high temperature) or frequent infections.</li><li>Sudden wheeziness or difficulty breathing.</li><li>Potentially life-threatening skin rashes (Stevens- Johnson syndrome, toxic epidermal necrolysis) have been reported (see Warnings and precautions).</li><li>Very rare cases of redness generalising to the whole body (generalised acute exanthematous pustulosis (AGEP)) (see section 2).</li><li>Mouth ulcers, cold sores and ulcers or soreness of your tongue.</li><li>Skin lumps or hives (raised, red or white, itchy patches of skin).</li><li>Blisters on your skin or inside your mouth, nose, vagina or bottom.</li><li>Inflammation of the eye which causes pain and redness.</li><li>The appearance of a rash or sunburn when you have been outside (even on a cloudy day).</li><li>Low levels of sodium in your blood.</li><li>Changes in blood tests.</li><li>Feeling weak, tired or listless, pale skin (anaemia)</li><li>Heart problems.</li><li>Jaundice (the skin and the whites of your eyes turn yellow). This can occur at the same time as unexpected bleeding or bruising.</li><li>Pains in your stomach, which can occur with blood in your faeces (stools).</li><li>Pains in your chest, muscles or joints and muscle weakness.</li><li>Arthritis.</li><li>Problems with your urine. Difficulty passing urine. Passing more or less urine than usual. Blood or cloudiness in your urine.</li><li>Kidney problems.</li><li>Sudden headache or stiffness of your neck, accompanied by fever (high temperature).</li><li>Problems controlling your movements.</li><li>Fits (convulsions or seizures).</li><li>Feeling unsteady or giddy.</li><li>Ringing or other unusual sounds in your ears.</li><li>Tingling or numbness in your hands and feet.</li><li>Seeing strange or unusual sights (hallucinations).</li><li>Depression.</li><li>Muscle pain and/or muscle weakness in HIV patients.</li><li>Loss of appetite.</li></ul><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>Psychotic disorder (a mental state in which you may lose touch with reality)</li><li>Plum-coloured, raised, painful sores on the limbs and sometimes on the face and neck with a fever (Sweets syndrome)</li><li>Drug reaction with eosinophilia and systemic symptoms (an allergic type reaction in which you may develop fever, skin rash, and abnormalities in blood and liver function tests (these may be signs of a multi-organ sensitivity disorder)).</li></ul><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p><br />Store below 30&deg;C.</p><p><br />Store in the original package in order to protect from light.</p><p><br />Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p><br />Do not use this medicine if you notice any visible signs of deterioration.</p><p><br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are trimethoprim and sulfamethoxazole.</p><p><br />Each tablet of Balkatrin 80 mg/400 mg Tablets contains 80 mg trimethoprim and 400 mg sulfamethoxazole.</p><p><br />The other ingredients are magnesium stearate, sodium starch glycolate, colloidal silicon dioxide, gelatin, sodium lauryl sulphate, maize starch and benzoic acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Balkatrin 80 mg/400 mg Tablets are white to off-white round-flat tablets embossed with “BALKATRIN” on both sides in colorless polyvinyl chloride-aluminum blisters.

Pack size: 20 Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Arab Pharmaceutical Manufacturing PSC<br />P.O. Box 42<br />Sult, Jordan<br />Tel: + (962-5) 3492200<br />Fax: + (962-5) 3492203</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07/2021; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يتكون بلقاترين 80 ملغم/ 400 ملغم أقراص (يسمى &ldquo;بلقاترين&rdquo; في هذه النشرة) من مضادين حيويين مختلفين يدعيان ثلاثي الميثوبريم وسولفاميثوكسازول (يُعرف أيضاً بثلاثي موكسازول المشترك)، يستخدمان لمعالجة العدوى التي يسببها نوع معين من البكتيريا. وكجميع المضادات الحيوية يعمل ثلاثي الميثوبريم وسولفاميثوكسازول فقط ضد بعض انواع البكتيريا. هذا يعني أنه مناسب فقط لمعالجة بعض أنواع العدوى.</p><p><br /><strong>يُستخدم بلقاترين في معالجة أو الوقاية من:</strong></p><ul><li>عدوى الرئة (التهاب رئوي أو الالتهاب الرئوي بالمتكيسة الجيروڤيسية) التي تسببها بكتيريا تسمى المتكيسة الرئوية الجيروڤيسية.</li><li>عدوى تسببها بكتيريا تسمى المُقوَّسة (داء المقوسات).</li></ul><p>&nbsp;</p><p><strong>يمكن استعمال بلقاترين في معالجة:</strong></p><ul><li>عدوى المثانة أو الجهاز البولي (عدوى الماء).</li><li>عدوى الجهاز التنفسي مثل التهاب القصبات.</li><li>عدوى الأذن مثل التهاب الأذن الوسطى.</li><li>عدوى تدعى داء النوكارديات، يمكن أن تصيب الرئتين، الجلد والدماغ.</li></ul><p>&nbsp;</p><p>يوصف بلقاترين للأطفال (&gt;&nbsp;12 عام إلى &lt;&nbsp;18 عام)&nbsp;وللبالغين (&gt; 18 عام).</p><p><br />يجب أخد التعليمات الرسمية للاستعمال الصحيح للمضادات الحيوية بعين الاعتبار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم بلقاترين إذا:</strong></p><ul><li>كنت تعاني من التحسس لسولفاميثوكسازول وثلاثي الميثوبريم أو ثلاثي موكسازول المشترك أو لإحدى المواد المستخدمة في تركيبة بلقاترين. (المذكورة في القسم 6).</li><li>كنت تعاني من التحسس لأدوية السلفوناميد. تشمل الأمثلة السلفونيل يوريات (مثل الغليكلازيد والغليبينكلاميد) أو مدرات البول الثيازيدية (مثل البندروفلوميثيازيد &ndash; أقراص الماء).</li><li dir="rtl">كنت تعاني من مشاكل شديدة في الكبد أو الكلى.</li><li dir="rtl">كان لديك في أي وقت مضى مشكلة في الدم تسبب الكدمات أو النزيف (قلة الصفيحات).</li><li dir="rtl">تم إخبارك أنك تعاني من مشكلة نادرة في الدم تسمى البرفرية والتي من الممكن أن تؤثر على الجلد أو الجهاز العصبي.</li><li dir="rtl">لا يجب إعطاء بلقاترين للرضع خلال ال 6 أسابيع الأولى من الولادة.</li></ul><p>&nbsp;</p><p>إذا لم تكن متأكداً فيما إذا كان أي من المذكور أعلاه ينطبق عليك، استشر طبيبك أو الصيدلي قبل تناول بلقاترين.</p><p><br /><strong>الاحتياطات والتحذيرات</strong><br />استشر طبيبك أو الصيدلي قبل استخدام بلقاترين إذا:</p><ul><li dir="rtl">كنت تعاني من حساسية شديدة أو ربو.</li><li dir="rtl">تم الإبلاغ عن طفوح جلدية مهددة للحياة (متلازمة ستيڤنز جونسون، أو تفاعل انحلال البشرة السمي الدوائي مع كثرة اليوزينات والأعراض الجهازية)&nbsp;مع استخدام ثلاثي الميثوبريم وسولفاميثوكسازول والتي تظهر في البداية على شكل بقع حمراء مركزية أو رقع دائرية غالباً مع نفط مركزية على الجذع.</li><li dir="rtl">عند البدء بالعلاج من الممكن أن يشير حدوث احمرار الجلد الشامل مع البثرات المصاحب للحمى إلى الاشتباه بحدوث تفاعل خطير يسمى البثرات الطفيلية الحادة الشاملة&nbsp;(انظر القسم 4)</li><li dir="rtl">البحث عن علامات إضافية تشمل التقرحات في الفم، الحنجرة، الأنف، الأعضاء التناسلية والتهاب الملتحمة (احمرار وتورم العينين).</li><li dir="rtl">تكون هذه الطفوح الجلدية المهددة للحياة غالباً مصحوبة بأعراض تشبه الإنفلونزا. وقد تتطور إلى تنفطات واسعة الانتشار أو تقشر الجلد.</li><li dir="rtl">الخطورة القصوى لحدوث تفاعلات جلدية خطيرة تكون في الأسابيع الأولى من العلاج.</li><li dir="rtl">إذا ظهر لديك متلازمة ستيڤنز جونسون أو انحلال البشرة السمي أو تفاعل الدواء مع كثرة اليوزينيّات والأعراض الجهازية مع استخدام بلقاترين فيجب ألا تعيد استخدام بلقاترين في أي وقت.</li><li dir="rtl">إذا ظهر لديك طفح أو أي من هذه الأعراض الجلدية توقف عن تناول بلقاترين اطلب مشورة عاجلة من الطبيب وأبلغه أنك تتناول هذا الدواء.</li><li dir="rtl">مرض الليمفاوي</li></ul><p style="margin-right:40px">تم الإبلاغ بحالات نادرة جداً عن ردود فعل مناعية شديدة بسبب اختلال في تفعيل خلايا الدم البيضاء مما يسبب التهابات (مرض الليمفاوي)، الذي يمكن أن يكون مهدد للحياة إذا لم يتم تشخيصه وعلاجه مبكراً. إذا حدثت لديك أعراض متعددة مثل الحمى، تورم في الغدد، الإحساس بالضعف، دوار، ضيق النفس، الكدمات، أو طفح جلدي بالتزامن أو بعدها بفترة قصيرة، تواصل مع طبيبك فوراً.</p><ul><li dir="rtl">إذا حدث لديك سعال غير متوقع يزيد سوءاً وضيق نفس، ابلغ طبيبك فوراً.</li><li dir="rtl">تم إبلاغك أنك تعاني من مشكلة نادرة بالدم تدعى البرفيرية، التي قد تؤثر على بشرتك أو جهازك العصبي.</li><li dir="rtl">لم يكن في جسمك ما يكفي من حمض الفوليك (ڤيتامين) &ndash; الأمر الذي قد يجعل بشرتك شاحبة ويجعلك تشعر بالتعب، الضعف، عسر التنفس. هذا يعرف بفقر الدم.</li><li dir="rtl">إذا كنت تعاني من مرض يسمى عوزِ سداسي فوسفات الجلوكوز النازع للهيدروجين والذي من الممكن أن يسبب اليرقان أو التكسر التلقائي لخلايا الدم الحمراء.</li><li dir="rtl">إذا كنت تعاني من مشكلة في التمثيل الغذائي تدعى بيلة الفينيل كيتون يوريا ولا تتبع نظام غذائي خاص يساعد وضعك.</li><li dir="rtl">كنت من كبار السن.</li><li dir="rtl">كنت تعاني من مرض في الكلى.</li><li dir="rtl">كنت تعاني من مشكلة شديدة في الدم مثل انخفاض خلايا الدم الحمراء (فقر الدم)، انخفاض خلايا الدم البيضاء (قلة الكريات البيض) أو انخفاض عدد الصفيحات، والذي من الممكن أن يسبب النزيف والكدمات (قلة الصفيحات).</li><li dir="rtl">كنت ناقص الوزن أو سيء التغذية.</li><li dir="rtl">أخبرك طبيبك أن لديك الكثير من البوتاسيوم في الدم. من الممكن أن يؤدي الاستخدام المصاحب لثلاثي الميثوبريم وسولفاميثوكسازول مع أدوية معينة، مكملات البوتاسيوم الغذائية والطعام الغني بالبوتاسيوم إلى الارتفاع الشديد لمستويات البوتاسيوم في الدم. قد تتضمن أعراض الارتفاع الشديد لمستويات البوتاسيوم تشنج العضلات، نبض القلب الغير منتظم، الاسهال، الغثيان، الدوار والصداع.</li></ul><p>&nbsp;</p><p><strong>الأدوية الأخرى وبلقاترين</strong><br />يرجى استشارة طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو من الممكن أن تتناول أية أدوية أخرى. وذلك لأن بلقاترين قد يؤثر في طريقة عمل بعض الأدوية. أيضاً قد تؤثر بعض الأدوية في طريقة عمل بلقاترين.</p><p><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية على وجه الخصوص:</p><ul><li>مدرات البول (أقراص الماء)، التي تساعد في زيادة كمية البول الذي تنتجه.</li><li>البيريميثامين، يستخدم لمعالجة والوقاية من الملاريا ويعالج الإسهال.</li><li>السيكلوسبورين، يستخدم بعد عمليات الزرع.</li><li>مميعات الدم مثل الوارفارين.</li><li>الفينيتوين، يستخدم لعلاج الصرع (النوبات).</li><li>الأدوية المستخدمة لعلاج السكري، مثل الغليبينكلاميد، الغليبيزيد أو التولبوتاميد (سلفونيل يوريات) وريباغليانيد</li><li>ريفامبيسين، مضاد حيوي.</li><li>أدوية علاج المشاكل التي تتعلق بضربات قلبك مثل الديجوكسين أو البروكايناميد.</li><li>الأمانتادين، يستخدم لعلاج داء باركنسون، التصلب اللويحي، الانفلونزا أو هربس نطاقي.</li><li>أدوية علاج فيروس العوز المناعي البشري، تسمى زيدوڤيودين أو لاميڤيودين.</li><li>الأدوية التي تزيد من كمية البوتاسيوم في الدم، مثل مدرات البول (أقراص الماء، التي تساعد في زيادة كمية البول الذي تنتجه مثل سباريتولاكتون)، الستيرويدات (مثل البريدنيزولون) والديجوكسين أو مثبط إنزيم محول الأنجيوتنسين(من الممكن أن تستعمل لعلاج ارتفاع ضغط الدم أو بعض مشاكل القلب).</li><li>آزاثيوبرين، من الممكن أن يستخدم عند المرضى بعد زراعة عضو أو علاج مشاكل الجهاز المناعي أو أمراض التهاب الأمعاء.</li><li>الميثوتريكسات، دواء يستخدم لعلاج السرطان أو بعض الأمراض التي تؤثر على الجهاز المناعي.</li><li>حمض الفولينيك</li><li>حبوب منع الحمل</li></ul><p>&nbsp;</p><p><strong>بلقاترين مع الطعام والشراب</strong><br />يجب عليك تناول بلقاترين مع بعض من الطعام او الشراب. فهذا سيمنعك من الشعور بالغثّي (الغثيان) او الإصابة بالإسهال. وبالتالي من المستحسن أن تتناوله مع الطعام، إلا أنه من الممكن لك أن تتناوله على معدة فارغة. اشرب كمية وافرة من السوائل مثل الماء عندما تتناول بلقاترين.</p><p><br /><strong>الحمل والرضاعة</strong><br />استشري طبيبِك أو الصيدلي قبل تناول هذا الدواء إذا كنتِ حاملاً أو مرضعة، تعتقدين بأنك حامل أو تخططين للحمل.</p><p><br /><strong>القيادة واستخدام الآلات</strong><br />لم تتم دراسة التأثير على القدرة على القيادة وتشغيل الآلات عند المرضى الذين يتناولون هذا الدواء.</p><p><br /><strong>يحتوي بلقاترين على حمض البنزويك والصوديوم</strong><br />يحتوي بلقاترين على حمض البنزويك. يحتوي كل قرص من بلقاترين 80 ملغم/ 400 ملغم أقراص على 0.30&nbsp;ملغم حمص البنزويك.</p><p><br />يحتوي بلقاترين على الصوديوم. يحتوي كل قرص من بلقاترين 80 ملغم/ 400 ملغم أقراص على 0.2 ملغم صوديوم. يحتوي هذا الدواء على أقل من 1&nbsp; ملمول&nbsp;صوديوم ( 23 ملغم)&nbsp;لكل قرص، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائماً تناول هذا الدواء تماماً كما وصفه لك طبيبك. يجب عليك استشارة طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p><br /><strong>الجرعة المعتادة</strong><br /><em>الجرعة المعتادة الموصى بها للعدوى الحادة</em></p><ul><li dir="rtl">البالغين (&gt;&nbsp;18 عام)</li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td colspan="2"><strong>الجرعة المعتادة</strong></td></tr><tr><td><strong>العمر</strong></td><td><strong>الأقراص</strong></td></tr><tr><td>&gt;18 عام</td><td>قرصين كل 12 ساعة</td></tr></tbody></table><p>&nbsp;</p><ul><li dir="rtl">الأطفال ما فوق 12 سنة (&gt;12&nbsp; عام إلى &lt;&nbsp;18 عام)</li></ul><p>&nbsp;الجرعة المعتادة للأطفال تعادل- تقريبا 6 ملغم من ثلاثي الميثوبريم و 30&nbsp;ملغم من سولفاميثوكسازول لكل كغم من وزن الجسم في اليوم، تعطى في جرعتين مقسمتين بالتساوي. جدولة الجرعات للأطفال تعتمد على عمر الطفل ووزنه كما هو مبين في الدول أدناه:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>العمر</strong></td><td><strong>الأقراص</strong></td></tr><tr><td>&gt; 12 عام&nbsp;إلى &lt; 18 عام&nbsp;</td><td>قرصين كل 12 ساعة</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>وزن الجسم</strong></td><td><strong>الأقراص</strong></td></tr><tr><td>&gt; 27 كغم</td><td>قرص كل 12 ساعة</td></tr><tr><td>&gt;&nbsp; 53 كغم</td><td>قرصين كل 12 ساعة</td></tr></tbody></table><p>&nbsp;</p><ul><li dir="rtl">يجب إعطاء بلقاترين لمدة 5 أيام على الأقل</li><li dir="rtl">تأكد من انهاءك للعلاج الذي وصفه لك طبيبك ببلقاترين</li></ul><p>&nbsp;</p><p>لا يعطى بلقاترين 80 ملغم/ 400 ملغم أقراص عادة للأطفال دون سن 12 عاما. إذا تم وصف هذا الدواء لطفلك الذي يقل عن سن 12 عاما يرجى التحدث إلى طبيبك&nbsp;أو الصيدلي للحصول على المزيد من المعلومات.</p><p><br /><strong>الجرعة الخاصة</strong><br />إن جرعة بلقاترين وطول مدة تناوله تعتمد على العدوى المصاب بها ومدى سوء الحالة. قد يصف طبيبك جرعة مختلفة أو طول مدة علاج مختلفة لبلقاترين من اجل:</p><ul><li dir="rtl">علاج عدوى الجهاز البولي (الماء).</li><li dir="rtl">معالجة والوقاية من عدوى الرئة الناتجة من البكتيريا المتكيسة الرئوية الجيروڤيسية.</li><li dir="rtl">معالجة العدوى الناتجة عن بكتيريا المقوّسة (داء المقوسات) أو النوكاردية (داء النوكارديات)</li></ul><p>.</p><p>إذا كنت تعاني من مشاكل في الكلى، قد يقوم طبيبك:</p><ul><li dir="rtl">بوصف جرعة مخفضة من بلقاترين.</li><li dir="rtl">بفحص الدم لمعرفة ما إذا ما كان الدواء يعمل بشكل فعال.</li></ul><p>&nbsp;</p><p>إذا تناولت بلقاترين لمدة طويلة قد يقوم طبيبك:</p><ul><li dir="rtl">بفحص الدم لمعرفة ما إذا ما كان الدواء يعمل بشكل فعال.</li><li dir="rtl">وصف حمض الفوليك )فيتامين( لتتناوله بشكل متزامن مع بلقاترين.</li></ul><p>&nbsp;</p><p><strong>إذا تناولت بلقاترين أكثر من اللازم</strong><br />إذا تناولت كمية زائدة من بلقاترين، اتصل بطبيبك أو اذهب للمستشفى فوراً. خذ علبة الدواء معك.</p><p>إذا أخذت كمية كبيرة من بلقاترين من الممكن أن:</p><ul><li dir="rtl">تصاب بالغثيان أو التقيؤ.</li><li dir="rtl">قد تشعر بالدوخة أو ارتباك.</li></ul><p>&nbsp;</p><p><strong>إذا نسيت تناول بلقاترين</strong></p><ul><li>إذا نسيت تناول جرعة، تناولها حالما تتذكر ذلك.</li><li>لا تأخذ جرعة مضاعفة لتعويض الجرعة التي نسيتها.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من أنها لا تصيب الجميع. قد تصاب بالآثار الجانبية التالية مع هذا الدواء.</p><p><br />توقف عن تناول ثلاثي الميثوبريم وسولفاميثوكسازول وأخبر طبيبك فوراً إذا عانيت من أي تفاعل تحسسي.</p><p><br /><em><strong>فرص حدوث التفاعل التحسسي نادرة جداً (تؤثر في أقل من 1&nbsp;لكل 10000 شخص)، علامات التفاعل التحسسي تشمل:&nbsp;<br />تفاعلات تحسسية:</strong></em></p><ul><li dir="rtl">صعوبة في التنفس.</li><li dir="rtl">فقدان الوعي.</li><li dir="rtl">تورم الوجه.</li><li dir="rtl">تورم الفم، اللسان أو الحلق الذي قد يكون أحمر ومؤلم و/أو يسبب صعوبة في البلع.</li><li dir="rtl">ألم في الصدر.</li><li dir="rtl">رقع حمراء على الوجه.</li></ul><p>&nbsp;</p><p><strong>شائعة جداً (أكثر من 1&nbsp;لكل 10 أشخاص)&nbsp;</strong></p><ul><li>مستويات عالية من البوتاسيوم في الدم الذي قد يسبب ضربات قلب غير طبيعية (خفقان).</li></ul><p>&nbsp;</p><p><strong>شائعة (أقل من لكل 10 أشخاص)</strong></p><ul><li>عدوى تسمى القلاع أو داء المبيضات الذي يؤثر على الفم أو المهبل. وهو ناتج من فطر.</li><li>الصداع.</li><li>الشعور بالغثيان.</li><li>الإسهال.</li><li>الطفوح جلدية.</li></ul><p>&nbsp;</p><p><strong>غير شائعة (أقل من لكل 100&nbsp;شخص)</strong></p><ul><li>القيء.</li></ul><p>&nbsp;</p><p><strong>نادرة جداً (أقل من لكل 10000&nbsp;شخص)&nbsp;</strong></p><ul><li>الحمى (ارتفاع الحرارة) أو العدوى المتكررة.</li><li>الصفير المفاجئ أو صعوبة التنفس.</li><li>تم الإبلاغ عن طفوح جلدية التي تحتمل أن تهدد الحياة متلازمة ستيڤنز جونسون، أو انحلال البشرة السمي (انظر قسم الاحتياطات و التحذيرات).</li><li>حالات نادرة جداً من احمرار الجلد الشامل لكل الجسم (تفاعل خطير يسمى البثرات الطفيلية الحادة الشاملة) (انظر القسم 2)</li><li>تقرحات الفم، قروح الزكام أو قرحات أو وجع اللسان.</li><li>كتل جلدية أو شرّى (رقع مرتفعة، حمراء أو بيضاء مسببة للحكة على الجلد).</li><li>تنفّط على الجلد أو داخل الفم، الأنف، المهبل أو الخلفية.</li><li>التهاب العين الذي يسبب الألم والاحمرار.</li><li>ظهور طفح أو حرق شمسي عندما تكون في الخارج (حتى في اليوم الغائم).</li><li>انخفاض مستويات الصوديوم في الدم.</li><li>تغيرات في فحوصات الدم.</li><li>الشعور بالضعف، التعب أو الفتور، شحوب الجلد (فقر الدم).</li><li>مشاكل قلبية.</li><li>اليرقان (تحول الجلد وبياض العينين إلى اللون الأصفر). قد يحدث هذا في نفس الوقت مع نزف أو كدمات غير متوقعة.</li><li>آلام في المعدة التي قد تحدث مع ظهور دم في البراز.</li><li>آلام في الصدر، العضلات أو المفاصل وضعف العضلات.</li><li>التهاب المفاصل.</li><li>مشاكل في التبول. صعوبة في التبول. التبول الزائد أو الأقل من المعتاد. وجود دم او كدرة في البول.</li><li>مشاكل الكلى.</li><li>صداع مفاجىء أو تصلب في الرقبة مصحوب بحمى (حرارة مرتفعة).</li><li>مشاكل في التحكم بالحركة.</li><li>نوبات (إختلاجات او أزمات)</li><li>الشعور بعدم الثبات أو الدوخة.</li><li>طنين في الأذنين او أصوات أخرى غير مألوفة.</li><li>تنميل أو خدران في يديك أو قدميك.</li><li>رؤية مشاهد غريبة أو غير اعتيادية (الهلوسات).</li><li>الاكتئاب.</li><li>ألم في العضلات و/أو ضعف في العضلات لمرضى ڤيروس عوز المناعة البشرية.</li><li>فقدان الشهية.</li></ul><p>&nbsp;</p><p><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتاحة)</strong></p><ul><li>مشاكل نفسية (حالة عقلية بحيث أنه من الممكن أن تفقد إدراكك للواقع)</li><li>تقرحات أرجوانية اللون، منتفخة، مؤلمة عند الأطراف وأحياناً على الوجه والرقبة مصاحبة للحمى(متلازمة سويت).</li><li>تفاعل الدواء مع كثرة اليوزينيّات والأعراض الجهازية (نوع تفاعل تحسسي تظهر فيه الحمى، طفح جلدي وتغيرات غير طبيعية في وظائف الدم والكبد (من الممكن أن تكون علامات لاضطراب تحسسي متعدد الأعضاء)).</li></ul><p>&nbsp;</p><p>إذا أصبح أي من الأعراض الجانبية خطير، أو إذا لاحظت حدوث أي من الأعراض الجانبية الغير مذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p><br />يحفظ عند درجة حرارة أقل من&nbsp; 30&deg; مئوية.&nbsp;</p><p><br />يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p><br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد&nbsp;&rdquo;EXP&ldquo;.&nbsp;يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p><br />لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p><br />لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي ثلاثي الميثوبريم وسولفاميثوكسازول.</p><p><br />يحتوي كل قرص من بلقاترين 80 ملغم/ 400 ملغم أقراص على 80 ملغم ثلاثي الميثوبريم و 400 ملغم سولفاميثوكسازول.</p><p><br />المواد الأخرى المستخدمة في التركيبة التصنيعية هي ستيرات المغنيسيوم، جليكولات نشا الصوديوم، ثاني أكسيد السيليكون الغروي، جيلاتين، لوريل كبريتات الصوديوم، نشا الذرة وحمض البنزويك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">بلقاترين 80 ملغم/ 400 ملغم أقراص هي أقراص دائرية مسطحة لونها أبيض مائل إلى الأبيض المصفر منقوش عليها&nbsp; &#39;&#39;BALKATRIN&#39;&#39;&nbsp;على&nbsp;كلتا الجهتين في&nbsp;أشرطة عديمة اللون من متعدد كلوريد الڤينيل-الألمنيوم.</p><p style="text-align:right">&nbsp;</p><p style="text-align:right">حجم العبوة: 20 قرص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة العربية لصناعة الأدوية المساهمة الخاصة<br />صندوق بريد&nbsp;42 &nbsp;<br />السلط، الأردن<br />&nbsp;هاتف: 3492200 (5-962)+<br />&nbsp;فاكس: 3492203 (5-962)+<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
              تمت مراجعة هذه النشرة بتاريخ  07/2021، رقم النسخة SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Balkatrin 80 mg/400 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of Balkatrin 80 mg/400 mg Tablet contains 400 mg sulfamethoxazole and 80 mg trimethoprim.

Excipients with known effect: Benzoic acid and sodium.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off-white round-flat tablets embossed with "BALKATRIN" on both sides.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Balkatrin tablets are indicated in children (&gt;12 to &lt;18 years old) and adults (&gt;18 years old) for the treatment of the following infections when owing to sensitive organisms (see section 5.1):</p><ul><li>Treatment and prevention of Pneumocystis jirovecii pneumonitis or &quot;PJP&quot;.</li><li>Treatment and prophylaxis of toxoplasmosis</li><li>Treatment of nocardiosis.</li></ul><p>&nbsp;</p><p>The following infections may be treated with Balkatrin where there is bacterial evidence of sensitivity to Balkatrin and good reason to prefer the combination of antibiotics in Balkatrin to a single antibiotic:</p><ul><li>Acute uncomplicated urinary tract infection</li><li>Acute otitis media</li><li>Acute exacerbation of chronic bronchitis</li></ul><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><strong>Posology</strong></em><br /><strong>General dosage recommendations</strong><br />Where dosage is expressed as &quot;tablets&quot; this refers to the adult tablet, i.e. 80 mg Trimethoprim BP&nbsp;and 400 mg Sulfamethoxazole BP. If other formulations are to be used appropriate adjustment should be made.</p><p>&nbsp;</p><p><strong>Standard dosage recommendations for acute infections</strong><br /><em>Adults (&gt;18 years old):</em></p><table border="1" cellspacing="1" cellpadding="1" style="width:730px"><tbody><tr><td colspan="2" style="width:727px"><strong>Standard Dosage</strong></td></tr><tr><td style="width:460px"><strong>Age</strong></td><td style="width:268px"><strong>Tablets</strong></td></tr><tr><td style="width:460px">&gt;18 years old</td><td style="width:268px">2 tablets every 12 hours</td></tr></tbody></table><p>&nbsp;</p><p><em>Children over 12 years old (&gt;12 to &lt;18 years old):</em><br />The standard dosage for children is equivalent to approximately 6 mg trimethoprim and 30 mg sulfamethoxazole per kg body weight per day, given in two equally divided doses. The schedules for children are according to the child&#39;s age and provided in the table below:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>Age</strong></td><td><strong>Tablets</strong></td></tr><tr><td>&gt;12 to &lt;18 years old</td><td>2 tablets every 12 hours</td></tr></tbody></table><p>&nbsp;</p><p>Treatment should be continued until the patient has been symptom free for two days; the majority will require treatment for at least 5 days. If clinical improvement is not evident after 7 days therapy, the patient should be reassessed.</p><p><br />As an alternative to Standard Dosage for acute uncomplicated lower urinary tract infections, shortterm therapy of 1 to 3 days duration has been shown to be effective.</p><p><br /><em>Elderly patients:</em><br />See Special Warnings and Precautions for Use (Section 4.4). Unless otherwise specified standard dosage applies.</p><p><br /><em>Impaired hepatic function:</em><br />No data are available relating to dosage in patients with impaired hepatic function.</p><p><br /><em>Impaired renal function:</em><br />Dosage recommendation:<br />Children (&gt;12 to &lt;18 years old) and adults (&gt;18 years old):</p><table border="1" cellspacing="1" cellpadding="1" style="width:631px"><tbody><tr><td style="width:442px"><strong>Creatinine Clearance (ml/min)</strong></td><td style="width:213px"><strong>Recommended Dosage</strong></td></tr><tr><td style="width:442px">&nbsp;&gt;30</td><td style="width:213px">2 tablets every 12 hours</td></tr><tr><td style="width:442px">&nbsp;15 to 30</td><td style="width:213px">1 tablet every 12 hours</td></tr><tr><td style="width:442px">&nbsp;&lt;15</td><td style="width:213px">Not recommended</td></tr></tbody></table><p>&nbsp;</p><p>No information is available for children aged 12 years and under with renal failure. See section 5.2 for the pharmacokinetics in the paediatric population with normal renal function of both components of Balkatrin, TMP and SMZ.</p><p><br />Measurements of plasma concentration of sulfamethoxazole at intervals of 2 to 3 days are recommended in samples obtained 12 hours after administration of co-trimoxazole (also known as sulfamethoxazole and trimethoprim). If the concentration of total sulfamethoxazole exceeds 150 microgram/ml then treatment should be interrupted until the value falls below 120 microgram/ml.</p><p><br /><strong>Pneumocystis jirovecii pneumonitis</strong><br /><em>Treatment- Children (&gt;12 to &lt;18 years old) and adults (&gt;18 years old):</em><br />A higher dosage is recommended, using 20 mg trimethoprim and 100 mg sulfamethoxazole per kg of body weight per day in two or more divided doses for two weeks. The aim is to obtain peak plasma or serum levels of trimethoprim of greater than or equal to 5 microgram/ml (verified in patients receiving 1-hour infusions of intravenous co-trimoxazole). (See 4.8 Undesirable Effects).</p><p><br /><em>Prevention - Adults (&gt;18 years old):</em><br />The following dose schedules may be used:<br />160 mg trimethoprim/800 mg sulfamethoxazole daily 7 days per week.<br />160 mg trimethoprim/800 mg sulfamethoxazole three times per week on alternate days.<br />320 mg trimethoprim/1600 mg sulfamethoxazole per day in two divided doses three times per week on alternate days.</p><p><br /><em>Prevention - Children (&gt;12 to &lt;18 years old):</em><br />The standard dosage for children is equivalent to approximately 6 mg trimethoprim and 30 mg sulfamethoxazole per kg body weight per day, given in two equally divided doses. The following dose schedules may be used for the duration of the period at risk:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>Age</strong></td><td><strong>Tablets</strong></td></tr><tr><td>&gt;12 to &lt;18 years old</td><td>2 tablets every 12 hours, seven days per week</td></tr><tr><td>&gt;12 to &lt;18 years old</td><td>2 tablets every 12 hours, three times per week on alternative days</td></tr><tr><td>&gt;12 to &lt;18 years old</td><td>2 tablets every 12 hours, three times per week on consecutive days</td></tr><tr><td>&gt;12 to &lt;18 years old</td><td>4 tablets once a day, three times per week on consecutive days</td></tr></tbody></table><p>&nbsp;</p><p>The daily dose given on a treatment day approximates to 150 mg trimethoprim/m<sup>2</sup>/day and 750 mg sulfamethoxazole/m<sup>2</sup>/day. The total daily dose should not exceed 320 mg trimethoprim and 1600 mg sulfamethoxazole.</p><p>&nbsp;</p><p><em>Nocardiosis - Adults (&gt;18 years old):</em><br />There is no consensus on the most appropriate dosage. Adult doses of 6 to 8 tablets daily for up to 3 months have been used.</p><p><br /><em>Toxoplasmosis:</em><br />There is no consensus on the most appropriate dosage for the treatment or prophylaxis of this condition. The decision should be based on clinical experience. For prophylaxis, however, the dosages suggested for prevention of Pneumocystis jirovecii pneumonitis may be appropriate.</p><p><br /><em><strong>Method of administration:</strong></em><br />Oral.</p><p><br />It may be preferable to take Balkatrin with some food or drink to minimise the possibility of&nbsp;gastrointestinal disturbances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance(s) sulphonamides, trimethoprim, co-trimoxazole or to any of the excipients listed in section 6.1.
• Balkatrin should not be given to patients with severe impairment of liver function.
• Contra-indicated in severe renal insufficiency where repeated measurements of the plasma concentration cannot be performed.
• Balkatrin should not be given to infants during the first 6 weeks of life.
• Balkatrin should not be given to patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulphonamides.
• Balkatrin should not be given to patients with acute porphyria.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Life threatening adverse reactions</strong><br />Fatalities, although very rare, have occurred due to severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, other blood dyscrasias and hypersensitivity of the respiratory tract.</p><ul><li>&nbsp;Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of co-trimoxazole.</li><li>Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment.</li><li>If symptoms or signs of SJS, TEN (e.g. progressive skin rash often with blisters or mucosal lesions) or DRESS (e.g. fever, eosinophilia) are present, Balkatrin treatment should be discontinued (see section 4.8).</li><li>The best results in managing SJS, TEN and DRESS come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis.</li><li>If the patient has developed SJS, TEN and DRESS with the use of Balkatrin, Balkatrin must not be re-started in this patient at any time.</li><li>At the start of treatment, the occurrence of a generalised febrile erythema associated with pustules, should raise the suspicion of acute generalised exanthematous pustulosis (AGEP) (see section 4.8); it requires cessation of treatment and contraindicates any new administration of Balkatrin alone or in combination with other drugs.</li></ul><p>&nbsp;</p><p><strong>Haemophagocytic lymphohistiocytosis (HLH)</strong><br />Cases of HLH have been reported very rarely in patients treated with co-trimoxazole. HLH is a lifethreatening syndrome of pathologic immune activation characterised by clinical signs and symptoms of an excessive systemic inflammation (e.g. fever, hepatosplenomegaly, hypertriglyceridaemia, hypofibrinogenaemia, high serum ferritin, cytopenias and haemophagocytosis). Patients who develop early manifestations of pathologic immune activation should be evaluated immediately. If diagnosis of HLH is established, Balkatrin treatment should be discontinued.</p><p><br /><strong>Respiratory toxicity</strong><br />Very rare, severe cases of respiratory toxicity, sometimes progressing to Acute Respiratory Distress Syndrome (ARDS), have been reported during co-trimoxazole treatment. The onset of pulmonary signs such as cough, fever, and dyspnoea in association with radiological signs of pulmonary infiltrates, and deterioration in pulmonary function may be preliminary signs of ARDS. In such circumstances, co-trimoxazole should be discontinued and appropriate treatment given.</p><p><br /><strong>Elderly patients</strong><br />Particular care is always advisable when treating elderly patients because, as a group, they are more susceptible to adverse reactions and more likely to suffer serious effects as a result particularly when complicating conditions exist, e.g. impaired kidney and/or liver function and/or concomitant use of other drugs.</p><p><br /><strong>Patients with renal impairment</strong><br />For patients with known renal impairment special measures should be adopted (see section 4.2).</p><p><br /><strong>Urinary output</strong><br />An adequate urinary output should be maintained at all times. Evidence of crystalluria in vivo is rare, although sulphonamide crystals have been noted in cooled urine from treated patients. In patients suffering from malnutrition the risk may be increased.</p><p>&nbsp;</p><p><strong>Folate</strong><br />Regular monthly blood counts are advisable when co-trimoxazole is given for long periods, or to folate deficient patients or to the elderly; since there exists a possibility of asymptomatic changes in haematological laboratory indices due to lack of available folate. Supplementation with folinic acid may be considered during treatment but this should be initiated with caution due to possible interference with antimicrobial efficacy (see section 4.5).</p><p><br /><strong>Patients with glucose-6-phosphate dehydrogenase deficiency</strong><br />In glucose-6-phosphate dehydrogenase (G-6-PD) deficient patients haemolysis may occur.</p><p><br /><strong>Patients with severe atopy or bronchial asthma</strong><br />Co-trimoxazole should be given with caution to patients with severe atopy or bronchial asthma.</p><p><br /><strong>Treatment of streptococcal pharyngitis due to Group A beta-haemolytic streptococci</strong><br />Co-trimoxazole should not be used in the treatment of streptococcal pharyngitis due to Group A beta-haemolytic streptococci; eradication of these organisms from the oropharynx is less effective than with penicillin.</p><p><br /><strong>Phenylalanine metabolism</strong><br />Trimethoprim has been noted to impair phenylalanine metabolism but this is of no significance in phenylketonuric patients on appropriate dietary restriction.</p><p><br /><strong>Patients with or at risk of porphyria</strong><br />The administration of Balkatrin to patients known or suspected to be at risk of porphyria should be avoided. Both trimethoprim and sulphonamides (although not specifically sulfamethoxazole) have been associated with clinical exacerbation of porphyria.</p><p><br /><strong>Patients with hyperkalaemia and hyponatraemia</strong><br />Close monitoring of serum potassium is warranted in patients at risk of hyperkalaemia and hyponatraemia.</p><p><br /><strong>Metabolic acidosis</strong><br />Co-Trimoxazole has been associated with metabolic acidosis when other possible underlying causes have been excluded. Close monitoring is always advisable when metabolic acidosis is suspected.</p><p><br /><strong>Patients with serious haematological disorders</strong><br />Except under careful supervision co-trimoxazole should not be given to patients with serious haematological disorders (see 4.8 Undesirable Effects). Co-trimoxazole has been given to patients&nbsp;receiving cytotoxic therapy with little or no additional effect on the bone marrow or peripheral blood.</p><p><br />The combination of antibiotics in co-trimoxazole should only be used where, in the judgement of the physician, the benefits of treatment outweigh any possible risks; consideration should be given to the use of a single effective antibacterial agent.y</p><p><br /><strong>Balkatrin contains benzoic acid and sodium</strong><br />Balkatrin contains benzoic acid. Each tablet of Balkatrin 80 mg/400 mg Tablets contains 0.30 mg benzoic acid.</p><p><br />Balkatrin contains sodium. Each tablet of Balkatrin 80 mg/400 mg Tablets contains 0.2 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Interaction with laboratory tests</em>: Trimethoprim may interfere with the estimation of serum/plasma creatinine when the alkaline picrate reaction is used. This may result in overestimation of serum/plasma creatinine of the order of 10%. The creatinine clearance is reduced: the renal tubular secretion of creatinine is decreased from 23% to 9% whilst the glomerular filtration remains unchanged.</p><p><br /><em>Zidovudine</em>: In some situations, concomitant treatment with zidovudine may increase the risk of haematological adverse reactions to co-trimoxazole. If concomitant treatment is necessary, consideration should be given to monitoring of haematological parameters.</p><p><br /><em>Cyclosporin:</em> Reversible deterioration in renal function has been observed in patients treated with co-trimoxazole and cyclosporin following renal transplantation.</p><p><br /><em>Rifampicin:</em> Concurrent use of rifampicin and co-trimoxazole results in a shortening of the plasma half-life of trimethoprim after a period of about one week. This is not thought to be of clinical significance.</p><p><br />When trimethoprim is administered simultaneously with drugs that form cations at physiological pH, and are also partly excreted by active renal secretion (e.g. procainamide, amantadine), there is the possibility of competitive inhibition of this process which may lead to an increase in plasma concentration of one or both of the drugs.</p><p><br /><em>Diuretics (thiazides):</em> In elderly patients concurrently receiving diuretics, mainly thiazides, there appears to be an increased risk of thrombocytopenia with or without purpura.</p><p>&nbsp;</p><p><em>Pyrimethamine: </em>Occasional reports suggest that patients receiving pyrimethamine at doses in excess of 25 mg weekly may develop megaloblastic anaemia should co-trimoxazole be prescribed concurrently.</p><p>&nbsp;</p><p><em>Warfarin: </em>Co-trimoxazole has been shown to potentiate the anticoagulant activity of warfarin via&nbsp;stereo-selective inhibition of its metabolism. Sulfamethoxazole may displace warfarin from plasmaalbumin&nbsp;protein-binding sites <em>in vitro.</em></p><p><br />Careful control of the anticoagulant therapy during treatment with Balkatrin is advisable.</p><p><br /><em>Phenytoin: </em>Co-trimoxazole prolongs the half-life of phenytoin and if co-administered could result in excessive phenytoin effect. Close monitoring of the patient&#39;s condition and serum phenytoin levels are advisable.</p><p><br /><em>Digoxin:</em> Concomitant use of trimethoprim with digoxin has been shown to increase plasma digoxin levels in a proportion of elderly patients.</p><p><br /><em>Methotrexate:</em> Co-trimoxazole may increase the free plasma levels of methotrexate. If cotrimoxazole is considered appropriate therapy in patients receiving other anti- folate drugs such as methotrexate, a folate supplement should be considered (see section 4.4).</p><p><br />Trimethoprim interferes with assays for serum methotrexate when dihydrofolate reductase from Lactobacillus casei is used in the assay. No interference occurs if methotrexate is measured by radioimmuno assay.</p><p><br /><em>Lamivudine: </em>Administration of trimethoprim /sulfamethoxazole 160 mg/800 mg (co-trimoxazole) causes a 40% increase in lamivudine exposure because of the trimethoprim component.&nbsp;Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulfamethoxazole.</p><p>&nbsp;</p><p>Interaction with sulphonylurea hypoglycaemic agents is uncommon but potentiation has been<br />reported.</p><p><br /><em>Hyperkalaemia:</em> Caution should be exercised in patients taking any other drugs that can cause hyperkalaemia, for example ACE inhibitors, angiotensin receptor blockers and potassium-sparing diuretics such as spironolactone. Concomitant use of trimethoprim-sulfamethoxazole (cotrimoxazole) may result in clinically relevant hyperkalaemia.</p><p><br /><em>Repaglinide:</em> Trimethoprim may increase the exposure of repaglinide which may result in hypoglycaemia.</p><p><br /><em>Folinic acid:</em> Folinic acid supplementation has been shown to interfere with the antimicrobial&nbsp;efficacy of trimethoprim-sulfamethoxazole. This has been observed in Pneumocystis&nbsp;jirovecii pneumonia prophylaxis and treatment.</p><p>&nbsp;</p><p><em>Contraceptives</em>: oral contraceptive failures have been reported with antibiotics. The mechanism of this effect has not been elucidated. Women on treatment with antibiotics should temporarily use a barrier method in addition to the oral contraceptive, or choose another method of contraception.</p><p><br /><em>Azathioprine:</em> There are conflicting clinical reports of interactions between azathioprine and trimethoprim-sulfamethoxazole, resulting in serious haematological abnormalities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />Trimethoprim and sulfamethoxazole cross the placenta and their safety in pregnant women has not been established. Case-control studies have shown that there may be an association between exposure to folate antagonists and birth defects in humans.</p><p><br />Trimethoprim is a folate antagonist and, in animal studies, both agents have been shown to cause foetal abnormalities (see section 5.3).</p><p><br />Balkatrin should not be used in pregnancy, particularly in the first trimester, unless clearly necessary. Folate supplementation should be considered if Balkatrin is used in pregnancy.</p><p><br />Sulfamethoxazole competes with bilirubin for binding to plasma albumin. As significantly maternally derived drug levels persist for several days in the newborn, there may be a risk of precipitating or exacerbating neonatal hyperbilirubinaemia, with an associated theoretical risk of kernicterus, when co-trimoxazole is administered to the mother near the time of delivery. This theoretical risk is particularly relevant in infants at increased risk of hyperbilirubinaemia, such as those who are preterm and those with glucose-6- phosphate dehydrogenase deficiency.</p><p><br /><strong>Breast-feeding</strong><br />The components of Balkatrin (trimethoprim and sulfamethoxazole) are excreted in breast milk. Administration of Balkatrin should be avoided in late pregnancy and in lactating mothers where the mother or infant has, or is at particular risk of developing, hyperbilirubinaemia. Additionally, administration of Balkatrin should be avoided in infants younger than eight weeks in view of the predisposition of young infants to hyperbilirubinaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effect of Balkatrin on driving performance or the ability to operate machinery. Further a detrimental effect on such activities cannot be predicted&nbsp;from the pharmacology of the drug. Nevertheless the clinical status of the patient and the adverse events profile of Balkatrin should be borne in mind when considering the patients ability to operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />The frequency categories associated with the adverse events below are estimates. For most events, suitable data for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on the indication.</p><p><br />Data from large published clinical trials were used to determine the frequency of very common to rare adverse events. Very rare adverse events were primarily determined from post-marketing experience data and therefore refer to reporting rate rather than a &quot;true&quot; frequency.</p><p><br /><strong>Tabulated list of adverse reaction</strong><br />The following convention has been used for the classification of adverse events in terms of frequency: Very common &ge;1/10, common &ge;1/100 and &lt;1/10, uncommon &ge;1/1000 and &lt;1/100, rare &ge;1/10,000 and &lt;1/1000, very rare &lt;1/10,000, not known - cannot be estimated from the available data.</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:842px"><tbody><tr><td style="width:445px"><strong>System Organ Class</strong></td><td style="width:126px"><strong>Frequency</strong></td><td style="width:286px"><strong>Side effects</strong></td></tr><tr><td rowspan="2" colspan="1" style="width:445px">Infections and infestations</td><td style="width:126px">Common</td><td style="width:286px">Overgrowth fungal.</td></tr><tr><td style="width:126px">Very rare</td><td style="width:286px">Pseudomembranous colitis</td></tr><tr><td style="width:445px">Blood and lymphatic system&nbsp;disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Leukopenia, neutropenia, thrombocytopenia,<br />agranulocytosis, anaemia megaloblastic,<br />aplastic anaemia, haemolytic anaemia,<br />methaemoglobinaemia, eosinophilia,<br />purpura, haemolysis in certain susceptible<br />G-6-PD deficient patients.</td></tr><tr><td style="width:445px">Immune system disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Serum sickness, anaphylactic reaction,<br />allergic myocarditis, hypersensitivity<br />vasculitis resembling Henoch-Schoenlein<br />purpura, periarteritis nodosa, systemic lupus<br />erythematosus.<br />Severe hypersensitivity reactions associated<br />with PJP*, rash, pyrexia, neutropenia,<br />thrombocytopenia, hepatic enzyme<br />increased, hyperkalaemia, hyponatraemia,&nbsp;rhabdomyolysis.</td></tr><tr><td rowspan="2" colspan="1" style="width:445px">Metabolism and nutrition&nbsp;disorders</td><td style="width:126px">Very common</td><td style="width:286px">Hyperkalaemia.</td></tr><tr><td style="width:126px">Very rare</td><td style="width:286px">Hypoglycaemia, hyponatraemia, decreased<br />appetite, metabolic acidosis</td></tr><tr><td rowspan="2" colspan="1" style="width:445px">Psychiatric disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Depression, hallucination.</td></tr><tr><td style="width:126px">Not known</td><td style="width:286px">Psychotic disorder.</td></tr><tr><td rowspan="2" colspan="1" style="width:445px">Nervous system disorders</td><td style="width:126px">Common</td><td style="width:286px">Headache.</td></tr><tr><td style="width:126px">Very rare</td><td style="width:286px">Meningitis aseptic *, convulsions,<br />neuropathy peripheral, ataxia, dizziness.</td></tr><tr><td style="width:445px">Ear and labyrinth disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Vertigo, tinnitus</td></tr><tr><td style="width:445px">Eye disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Uveitis.</td></tr><tr><td style="width:445px">Respiratory, thoracic and&nbsp;mediastinal disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Cough *, dyspnoea*, lung infiltration*.</td></tr><tr><td rowspan="3" colspan="1" style="width:445px">Gastrointestinal disorders</td><td style="width:126px">Common</td><td style="width:286px">Nausea, diarrhoea.</td></tr><tr><td style="width:126px">Uncommon</td><td style="width:286px">Vomiting.</td></tr><tr><td style="width:126px">Very rare</td><td style="width:286px">Glossitis, stomatitis, pancreatitis.</td></tr><tr><td colspan="1" style="width:445px">Hepatobiliary disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Transaminases increased, blood bilirubin<br />increased, cholestatic jaundice, hepatic<br />necrosis.</td></tr><tr><td colspan="1" rowspan="3" style="width:445px">Skin and subcutaneous tissue&nbsp;disorders*</td><td style="width:126px">Common</td><td style="width:286px">Rash.</td></tr><tr><td style="width:126px">Very rare</td><td style="width:286px">Photosensitivity reaction, angiodema,<br />dermatitis exfoliative, fixed drug eruption,<br />erythema multiforme, Stevens-Johnson<br />syndrome (SJS) *, toxic epidermal necrolysis<br />(TEN) *. Acute generalised exanthematous<br />pustulosis (AGEP).</td></tr><tr><td style="width:126px">Not known</td><td style="width:286px">Acute febrile neutrophilic dermatosis<br />(Sweet&#39;s syndrome), Drug reaction with<br />eosinophilia and systemic symptoms<br />(DRESS)*</td></tr><tr><td colspan="1" style="width:445px">Musculoskeletal and connective&nbsp;tissue disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Arthralgia, myalgia.</td></tr><tr><td colspan="1" style="width:445px">Renal and urinary disorders</td><td style="width:126px">Very rare</td><td style="width:286px">Renal impairment (sometimes reported as<br />renal failure), tubulointerstitial nephritis and<br />uveitis syndrome, renal tubular acidosis</td></tr></tbody></table><p>* see description of selected adverse reactions</p><p>&nbsp;</p><p><strong>Description of selected adverse reactions</strong><br /><em>Aseptic meningitis</em><br />Aseptic meningitis was rapidly reversible on withdrawal of the drug, but recurred in a number of cases on re-exposure to either co-trimoxazole or to trimethoprim alone.</p><p><br /><em>Pulmonary hypersensitivity reactions</em><br />Cough, dyspnoea and lung infiltration may be early indicators of respiratory hypersensitivity which, while very rare, has been fatal.</p><p><br /><em>Hepatobiliary disorders</em><br />Jaundice cholestatic and hepatic necrosis may be fatal.</p><p><br /><em>Severe cutaneous adverse reactions (SCARs)</em><br />Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported to be life-threatening (see section 4.4).</p><p><br />As with any other drug, allergic reactions such as an itchy rash and hives may occur in patients with hypersensitivity to the components of the drug. Very rare cases of acute generalised exanthematous pustulosis (AGEP) have been observed (see section 4.4).</p><p><br /><em>Effects associated with Pneumocystis jirovecii Pneumonitis (PJP) management</em><br />Severe hypersensitivity reactions, rash, pyrexia, neutropenia, thrombocytopenia, hepatic enzyme increased, hyperkalaemia, hyponatraemia, rhabdomyolysis.</p><p><br />At the high dosages used for PJP management severe hypersensitivity reactions have been reported, necessitating cessation of therapy. Severe hypersensitivity reactions have been reported in PJP patients on re-exposure to co-trimoxazole, sometimes after a dosage interval of a few days.</p><p><br />Rhabdomyolysis has been reported in HIV positive patients receiving trimethoprimsulfamethoxazole for prophylaxis or treatment of PJP.</p><p><br /><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong><br />Nausea, vomiting, dizziness and confusion are likely signs/symptoms of overdosage. Bone marrow depression has been reported in acute trimethoprim overdosage.</p><p><br /><strong>Treatment</strong><br />If vomiting has not occurred, induction of vomiting may be desirable. Gastric lavage may be useful, though absorption from the gastrointestinal tract is normally very rapid and complete within approximately two hours. This may not be the case in gross overdosage. Dependant on the status of renal function administration of fluids is recommended if urine output is low.</p><p><br />Both trimethoprim and active sulfamethoxazole are moderately dialysable by haemodialysis.&nbsp;Peritoneal dialysis is not effective.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong><br />Antibacterials for systemic use - Sulfonamides and trimethoprim, incl. derivatives; ATC code: J01EE01</p><p><br /><strong>Mechanism of Action</strong><br />Sulfamethoxazole competitively inhibits the utilisation of para-aminobenzoic acid in the synthesis of dihydrofolate by the bacterial cell resulting in bacteriostasis. Trimethoprim reversibly inhibits bacterial dihydrofolate reductase (DHFR), an enzyme active in the folate metabolic pathway converting dihydrofolate to tetrahydrofolate. Depending on the conditions the effect may be bactericidal. Thus trimethoprim and sulfamethoxazole block two consecutive steps in the biosynthesis of purines and therefore nucleic acids essential to many bacteria. This action produces marked potentiation of activity <em>in vitro</em> between the two agents.</p><p><br />Trimethoprim binds to plasmodial DHFR but less tightly than to the bacterial enzyme. Its affinity for mammalian DHFR is some 50,000 times less than for the corresponding bacterial enzyme.</p><p>&nbsp;</p><p><strong>Mechanism of resistance</strong><br /><em>In vitro</em> studies have shown that bacterial resistance can develop more slowly with both sulfamethoxazole and trimethoprim in combination that with either sulfamethoxazole or&nbsp;trimethoprim alone.</p><p><br />Resistance to sulfamethoxazole may occur by different mechanisms. Bacterial mutations cause an increase the concentration of PABA and thereby out-compete with sulfamethoxazole resulting in a reduction of the inhibitory effect on dihydropteroate synthetase enzyme. Another resistance mechanism is plasmid-mediated and results from production of an altered dihydropteroate synthetase enzyme, with reduced affinity for sulfamethoxazole compared to the wild-type enzyme.</p><p><br />Resistance to trimethoprim occurs through a plasmid-mediated mutation which results in production of an altered dihydrofolate reductase enzyme having a reduced affinity for&nbsp;trimethoprim compared to the wild-type enzyme.</p><p><br />Trimethoprim binds to plasmodial DHFR but less tightly than to bacterial enzyme. Its affinity for mammalian DHFR is some 50,000 times less than for the corresponding bacterial enzyme.</p><p><br />Many common pathogenic bacteria are susceptible in <em>vitro </em>to trimethoprim and sulfamethoxazole at concentrations well below those reached in blood, tissue fluids and urine after the administration of recommended doses. In common with other antibiotics, however, in vitro activity does not necessarily imply that clinical efficacy has been demonstrated and it must be noted that satisfactory susceptibility testing is achieved only with recommended media free from inhibitory substances, especially thymidine and thymine.</p><p><br /><strong>Susceptibility testing breakpoints</strong><br /><em>EUCAST (European Committee on Antimicrobial Susceptibility Testing) limits</em><br /><em>Enterobacteriaceae</em>: S&le; 2 R&gt; 4<br /><em>S. maltophilia</em>: S&le; 4 R&gt; 4<br /><em>Acinetobacter: </em>S&le; 2 R&gt; 4<br /><em>Staphylococcus:</em> S&le; 2 R&gt; 4<br /><em>Enterococcus</em>: S&le; 0.032 R&gt; 1<br /><em>Streptococcus ABCG: </em>S&le; 1 R&gt; 2<br /><em>Streptococcus pneumoniae:</em> S&le; 1 R&gt; 2<br /><em>Hemophilus influenza:</em> S&le; 0.5 R&gt; 1<br /><em>Moraxella catarrhalis:</em> S&le;0.5 R &gt;1<br /><em>Psuedomonas aeruginosa and other non-enterobacteriaceae:</em> S&le; 2* R&gt; 4*<br />S = susceptible, R = resistant. *These are CLSI breakpoints since no EUCAST breakpoints are currently available for these organisms.</p><p>&nbsp;</p><p>Trimethoprim: sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as trimethoprim concentration.</p><p><br /><strong>Antibacterial Spectrum</strong><br />The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. This information gives only an approximate guidance on probabilities whether microorganisms will be susceptible to trimethoprim/sulfamethoxazole or not.</p><p>&nbsp;</p><p>Trimethoprim/sulfamethoxazole susceptibility against a number of bacteria are shown in the table below:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>Commonly susceptible species:</strong></td></tr><tr><td><strong>Gram-positive aerobes:</strong><br /><em>Staphylococcus aureus<br />Staphylococcus saprophyticus<br />Streptococcus pyogenes</em></td></tr><tr><td><strong>Gram-negative aerobes:</strong><br /><em>Enterobacter cloacae<br />Haemophilus influenzae<br />Klebsiella oxytoca<br />Moraxella catarrhalis<br />Salmonella spp.<br />Stenotrophomonas maltophilia<br />Yersinia spp.</em></td></tr><tr><td><strong>Species for which acquired resistance may be a problem:</strong></td></tr><tr><td><strong>Gram-positive aerobes:</strong><br /><em>Enterococcus faecalis<br />Enterococcus faecium<br />Nocardia spp.<br />Staphylococcus epidermidis<br />Streptococcus pneumoniae</em></td></tr><tr><td><p><strong>Gram-negative aerobes:</strong><br /><em>Citrobacter spp.<br />Enterobacter aerogenes<br />Escherichia coli<br />Klebsiella pneumoniae<br />Klebsiella pneumonia<br />Proteus mirabilis<br />Proteus vulgaris<br />Providencia spp.<br />Serratia marcesans</em></p></td></tr><tr><td><strong>Inherently resistant organisms:</strong></td></tr><tr><td><strong>Gram-negative aerobes:</strong><br /><em>Pseudomonas aeruginosa<br />Shigella spp.<br />Vibrio cholera</em></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong><br />After oral administration trimethoprim and sulfamethoxazole are rapidly and nearly completely absorbed. The presence of food does not appear to delay absorption. Peak levels in the blood occur between one and four hours after ingestion and the level attained is dose related. Effective levels persist in the blood for up to 24 hours after a therapeutic dose. Steady state levels in adults are reached after dosing for 2-3 days. Neither component has an appreciable effect on the concentrations achieved in the blood by the other.</p><p><br /><strong>Distribution</strong><br />Approximately 50% of trimethoprim in the plasma is protein bound.</p><p>&nbsp;</p><p>Tissue levels of trimethoprim are generally higher than corresponding plasma levels, the lungs and kidneys showing especially high concentrations. Trimethoprim concentrations exceed those in plasma in the case of bile, prostatic fluid and tissue, saliva, sputum and vaginal secretions. Levels in the aqueous humor, breast milk, cerebrospinal fluid, middle ear fluid, synovial fluid and tissue (intestinal) fluid are adequate for antibacterial activity. Trimethoprim passes into amniotic fluid and foetal tissues reaching concentrations approximating those of maternal serum.</p><p><br />Approximately 66% of sulfamethoxazole in the plasma is protein bound. The concentration of active sulfamethoxazole in amniotic fluid, aqueous humour, bile, cerebrospinal fluid, middle ear fluid, sputum, synovial fluid and tissue (interstitial) fluids is of the order of 20 to 50% of the plasma concentration.</p><p><br /><strong>Biotransformation</strong></p><p>Renal excretion of intact sulfamethoxazole accounts for 15-30% of the dose. This drug is more extensively metabolised than trimethoprim, via acetylation, oxidation or glucuronidation. Over a 72 hour period, approximately 85% of the dose can be accounted for in the urine as unchanged drug plus the major (N4-acetylated) metabolite.</p><p><br /><strong>Elimination</strong><br />The half-life of trimethoprim in man is in the range 8.6 to 17 hours in the presence of normal renal function. It is increased by a factor of 1.5 to 3.0 when the creatinine clearance is less than 10 ml/minute. There appears to be no significant difference in elderly patients compared with young patients.</p><p><br />The principal route of excretion of trimethoprim is renal and approximately 50% of the dose is excreted in the urine within 24 hours as unchanged drug. Several metabolites have been identified in the urine. Urinary concentrations of trimethoprim vary widely.</p><p><br />The half-life of sulfamethoxazole in man is approximately 9 to 11 hours in the presence of normal renal function.</p><p><br />There is no change in the half-life of active sulfamethoxazole with a reduction in renal function but there is prolongation of the half-life of the major, acetylated metabolite when the creatinine clearance is below 25 ml/minute.</p><p>&nbsp;</p><p>The principal route of excretion of sulfamethoxazole is renal; between 15% and 30% of the dose recovered in the urine is in the active form.</p><p><br />The pharmacokinetics in the paediatric population with normal renal function of both components of Co-Trimoxazole, TMP and SMZ are age dependent. Elimination of TMP-SMZ is reduced in neonates, during the first two months of life, thereafter both TMP and SMZ show a higher elimination with a higher body clearance and a shorter elimination half-life. The differences are most prominent in young infants (&gt; 1.7 months up to 24 months) and decrease with increasing age, as compared to young children (1 year up to 3.6 years), children (7.5 years and &lt; 10 years) and adults (see section 4.2).</p><p><br />In elderly patients there is a reduced renal clearance of sulfamethoxazole.</p><p><br /><strong>Special patient population</strong><br /><em>Renal impairment</em><br />The elimination half-life of trimethoprim is increased by a factor of 1.5-3.0 when the creatinine clearance is less than 10 mL/minute. When the creatinine clearance falls below 30 ml/min the&nbsp;dosage of co-trimoxazole should be reduced (see section 4.2).</p><p><br /><em>Hepatic impairment</em><br />Caution should be exercised when treating patients with severe hepatic parenchymal damage as there may be changes in the absorption and biotransformation of trimethoprim and sulfamethoxazole.</p><p><br /><em>Elderly patients</em><br />In elderly patients, a slight reduction in renal clearance of sulfamethoxazole but not trimethoprim has been observed.</p><p><br /><em>Paediatric population</em><br />See special dosage regimen (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At doses in excess of recommended human therapeutic dose, trimethoprim and sulfamethoxazole have been reported to cause cleft palate and other foetal abnormalities in rats, findings typical of a folate antagonist. Effects with trimethoprim were preventable by administration of dietary folate. In rabbits, foetal loss was seen at doses of trimethoprim in excess of human therapeutic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Magnesium stearate<br />- Sodium starch glycolate<br />- Colloidal silicon dioxide<br />- Gelatin<br />- Sodium lauryl sulphate<br />- Maize starch<br />- Benzoic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See drug interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                60 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colorless polyvinyl chloride-aluminum blisters.</p><p><br />Pack size: 20 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trimethoprim interferes with assays for serum methotrexate when dihydrofolate reductase from<em> Lactobacillus casei</em>&nbsp; is used in the assay. No interference occurs if methotrexate is measured by radioimmuno assay.</p><p><br />Trimethoprim may interfere with the estimation of serum/plasma creatinine when the alkaline picrate reaction is used. This may result in overestimation of serum/plasma creatinine of the order of 10%. Functional inhibition of the renal tubular secretion of creatinine may product a spurious fall in the estimated rate of creatinine clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Arab Pharmaceutical Manufacturing PSC
P.O. Box 42
Sult, Jordan
Tel: + (962-5) 3492200
Fax: + (962-5) 3492203
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03 December 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>